Trial reportCirculation. Cardiovascular interventions2020
One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism.
Trial report in Circulation. Cardiovascular interventions, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02396758 (Study of the OPTtimum Duration of Acoustic Pulse ThromboLYSis ProcEdure in the Treatment of Acute Submassive Pulmonary Embolism), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the OPTtimum Duration of Acoustic Pulse ThromboLYSis ProcEdure in the Treatment of Acute Submassive Pulmonary Embolism
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Patient-Reported Outcomes in Venous Thromboembolism: A Systematic Review of the Literature, Current Challenges, and Ways Forward.Journal of the American Heart Association · 2023Pooled it
- Current Insights for Catheter-Directed Therapies in Acute Pulmonary Embolism: Systematic Review and Our Single-Center Experience.Anatolian journal of cardiology · 2023Pooled it
- Trial
- Mechanical thrombectomy improves left ventricular filling in intermediate-high risk pulmonary embolism: the role of ventricular interdependence.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Post-pulmonary embolism cardiac impairment and chronic thromboembolic pulmonary hypertension after ultrasound-assisted catheter-directed thrombolysis for acute pulmonary embolism.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Plugging the Gaps: Catheter-Based Interventions in Elderly Patients Presenting With Pulmonary Embolism.JACC. Advances · 2025Article
- Pulmonary Embolism in Women in the Era of Expanding Advanced Therapies.Current cardiology reports · 2025Review
- Ultrasound-Assisted Catheter-Directed Thrombolytic Therapy Vs. Anticoagulation in Acute Intermediate-High Risk Pulmonary Embolism: A Quasi-Experimental Study.Anatolian journal of cardiology · 2025Article
- Ultrasound-mediated catheter delivery of tissue plasminogen activator promotes thrombolysis by altering fibrin fiber thickness and clot permeability.Haematologica · 2025Article
- Role of Transcatheter Treatment in Intermediate-to High-risk Pulmonary Embolism.Interventional cardiology (London, England) · 2025Review
- Research progress in interventional therapy for acute intermediate-high-risk and high-risk pulmonary embolism.Journal of thoracic disease · 2024Review
- High and intermediate risk pulmonary embolism in the ICU.Intensive care medicine · 2024Review
- Catheter Interventions for Pulmonary Embolism: Mechanical Thrombectomy Versus Thrombolytics.Methodist DeBakey cardiovascular journal · 2024Review
- Evolving Management Trends and Outcomes in Catheter Management of Acute Pulmonary Embolism.Journal of cardiothoracic and vascular anesthesia · 2022Review
- Assessing quality of life after pulmonary embolism: Comparing results from the PEmb-QoL with semistructured interviews.Research and practice in thrombosis and haemostasis · 2022Article
- Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population.Current oncology reports · 2022Review
- Concise Review of the Rationale for Pulmonary Embolism Treatment and Endovascular Device Therapies.Current cardiology reviews · 2022Review
- Health-related quality-of-life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology.Research and practice in thrombosis and haemostasis · 2021Review
- Longer-Term Outcomes Following Mechanical Thrombectomy for Intermediate- and High-Risk Pulmonary Embolism: 6-Month FLASH Registry Results.Journal of the Society for Cardiovascular Angiography & InterventionsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccelerated tPA (tissue-type plasminogen activator) dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis improve short-term computed tomographic-measured right ventricular (RV)-to-left ventricular diameter ratio in massive and submassive pulmonary embolism. The impact on RV remodeling, functional status, and quality of life over the long-term remains unclear.
methodsTo study 1-year changes in RV remodeling, functional status, and quality of life, we assessed patients with acute submassive pulmonary embolism randomly assigned to 1 of 4 tPA dosing regimens for ultrasound-facilitated, catheter-directed fibrinolysis in the OPTALYSE-PE trial (Optimum Duration and Dose of r-tPA With the Acoustic Pulse Thrombolysis Procedure for Intermediate-Risk Pulmonary Embolism; 8 mg/2 hours, 8 mg/4 hours, 12 mg/6 hours, and 24 mg/6 hours). Echocardiographic assessment included RV-to-left ventricular diameter ratio within 4 hours of treatment end, and at 48 hours, 30 days, 90 days, and 1 year. Functional status was assessed by 6-minute walk test at 30 days, 90 days, and 1 year and PROMIS-PF-6b scores at 30 days, 90 days, 180 days, 270 days, and 1 year. Quality of life was evaluated by PEmb-QOL scores at 30 days, 90 days, 180 days, 270 days, and 1 year.
resultsMean RV-to-left ventricular diameter ratio decreased from baseline to 4 hours and further at 48 hours and 30 days, with reductions maintained at 90 days and 1 year in all groups. Mean 6-minute walk distance, PROMIS-PF-6b, and PEmb-QOL scores improved over the course of 1 year in all groups.
conclusionsAccelerated lower-dose tPA regimens for ultrasound-facilitated, catheter-directed fibrinolysis resulted in sustained recovery of RV-to-left ventricular diameter ratio and tricuspid annular plane systolic excursion and improvements in functional status and quality of life over 1 year. Registration: URL: https://www.ClinicalTrials.gov. Unique Identifier: NCT02396758.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.